3-(benzo[d]oxazol-2-yl)-7-(dimethylamino)-2H-chromen-2-one | 35773-51-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 3-(benzo[d]oxazol-2-yl)-7-(dimethylamino)-2H-chromen-2-one
• 英文别名: 3-benzooxazol-2-yl-7-dimethylamino-chromen-2-one；3-(Benzo[d]oxazol-2-yl)-7-(dimethylamino)-2h-chromen-2-one；3-(1,3-benzoxazol-2-yl)-7-(dimethylamino)chromen-2-one
• CAS: 35773-51-4
• 化学式: C₁₈H₁₄N₂O₃
• 分子量: 306.321
• InChiKey: VFDCDEBMRUPSFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  55.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基苯酚 在 哌啶 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 40.0h， 生成 3-(benzo[d]oxazol-2-yl)-7-(dimethylamino)-2H-chromen-2-one
  参考文献：
  名称：

  Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy

  摘要：

  The underlying cause of spinal muscular atrophy (SMA) is a deficiency of the survival motor neuron (SMN) protein. Starting from hits identified in a high-throughput screening campaign and through structure activity relationship investigations, we have developed small molecules that potently shift the alternative splicing of the SMN2 exon 7, resulting in increased production of the full-length SMN mRNA and protein. Three novel chemical series, represented by compounds 9, 14, and 20, have been optimized to increase the level of SMN protein by >50% in SMA patient-derived fibroblasts at concentrations of <160 nM. Daily administration of these compounds to severe SMA Delta 7 mice results in an increased production of SMN protein in disease-relevant tissues and a significant increase in median survival time in a dose-dependent manner. Our work supports the development of an orally administered small molecule for the treatment of patients with SMA.

  DOI：

  10.1021/acs.jmedchem.6b00460

文献信息

• [EN] COUMARINES USEFUL AS BIOMARKERS<br/>[FR] COUMARINES CONVENANT COMME BIOMARQUEURS
  申请人：NOVARTIS AG

  公开号：WO2003074519A1

  公开（公告）日：2003-09-12

  The invention provides compounds of formula (I), wherein R, R1, R2, R3 and R4 are as defined in the description, and their preparation. The compounds of formula I are useful as biomarkers.

  该发明提供了式（I）的化合物，其中R、R1、R2、R3和R4如描述中所定义，以及它们的制备。式I的化合物可用作生物标志物。
• Coumarines useful as biomarkers
  申请人：Auberson Yves

  公开号：US20050169837A1

  公开（公告）日：2005-08-04

  The invention provides compounds of formula (I), wherein R, R 1 , R 2 , R 3 and R 4 are as defined in the description, and their preparation. The compounds of formula I are useful as biomarkers.

  本发明提供了式(I)的化合物，其中R、R1、R2、R3和R4如描述中所定义，并提供它们的制备方法。式(I)的化合物可用作生物标志物。
• COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：PTC Therapeutics Inc.

  公开号：US20150119380A1

  公开（公告）日：2015-04-30

  Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.

  本文提供了用于治疗脊髓性肌萎缩症的化合物、其组合物及与其一起使用的用途。在一个具体实施例中，本文提供了一种可以用来调节SMN2基因转录的mRNA中包含外显子7的形式化合物。在另一个具体实施例中，本文提供了一种可以用来调节SMN1基因转录的mRNA中包含外显子7的形式化合物。在另一个实施例中，本文提供了一种可以用来调节SMN1和SMN2基因转录的mRNA中包含外显子7的形式化合物。
• COUMARINES USEFUL AS BIOMARKERS
  申请人：Novartis AG

  公开号：EP1483262A1

  公开（公告）日：2004-12-08
• US7569337B2
  申请人：——

  公开号：US7569337B2

  公开（公告）日：2009-08-04